

# ASX Release

## Completion of Share Consolidation

**Perth, Australia – 22 November 2019:** SUDA Pharmaceuticals Limited (ASX: SUD), a leader in oro-mucosal drug delivery, is pleased to advise that it has completed the consolidation of its share capital on a one (1) for twenty-five (25) basis (the “Consolidation”). The Consolidation was approved by shareholders at the Annual General Meeting of the Company held on 12 November 2019.

As a result of the Consolidation, the post consolidation shares and options in the Company are as follows:

Securities	Number of securities on issue (Pre-consolidation)	Number of securities on issue (Post-consolidation)
Fully-paid Ordinary Shares	3,556,371,635	142,254,397
Listed Options - SUDOC	698,908,634	27,956,286
Listed Options - SUDOD	517,206,121	20,688,051
Unlisted Options - various	27,500,000	1,100,000

New holding statements are in the process of being despatched to shareholders and optionholders to advise them of their holdings on a post-consolidation basis.

In accordance with the timetable for the Consolidation, normal trading will commence on Monday, 25 November 2019.

Further information:

**Paul Hopper**

**Executive Chairman**

**SUDA Pharmaceuticals Ltd**

Tel: +61 (0) 406 671 515

phopper@sudapharma.com

**NOTES TO EDITORS:****About SUDA Pharmaceuticals Ltd**

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of: migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety and cancer. For more information, visit [www.sudapharma.com](http://www.sudapharma.com)